Overview

Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.